

Biocatalysis and Biotransformation: Green Chemistry Approaches in Drug Synthesis

David Schneid*

Department of Biochemistry, University of Oxford, UK

Introduction

The pharmaceutical industry, while vital for human health, has historically relied on synthetic methodologies that often involve harsh reaction conditions, toxic solvents, and the generation of significant waste. These practices contradict the principles of green chemistry, which advocate for sustainable and environmentally benign processes. In response to increasing environmental concerns and regulatory pressures, the industry is actively seeking alternative approaches. Biocatalysis and biotransformation, utilizing enzymes or whole cells, have emerged as powerful tools for achieving greener and more efficient drug synthesis. These methods offer numerous advantages, including high selectivity, mild reaction conditions, and the potential for utilizing renewable resources. This article delves into the description of these approaches and their significance in the context of green chemistry, culminating in a comprehensive conclusion [1].

Description

Biocatalysis: Enzymes as catalysts

Biocatalysis utilizes enzymes, biological catalysts, to perform specific chemical transformations. Enzymes are highly selective, often catalyzing reactions with exquisite regio-, chemo-, and stereoselectivity [2]. This inherent selectivity minimizes the formation of unwanted byproducts, reducing the need for extensive purification steps.

Types of enzymes:

Oxidoreductases: Catalyze oxidation-reduction reactions, crucial for introducing or modifying functional groups.

Transferases: Facilitate the transfer of functional groups between molecules.

Hydrolases: Catalyze hydrolysis reactions, breaking down bonds using water.

Lyases: Catalyze bond cleavage without hydrolysis or oxidation.

Isomerases: Catalyze isomerization reactions, converting one isomer to another.

Ligases: Catalyze the joining of two molecules.

Advantages of biocatalysis

High selectivity: Enzymes often exhibit high regio-, chemo-, and stereoselectivity, leading to fewer byproducts and simplified purification [3].

Mild reaction conditions: Reactions typically occur at ambient temperatures and pressures, reducing energy consumption.

Reduced waste generation: High selectivity and mild conditions minimize waste production.

Use of renewable resources: Enzymes can be produced from renewable sources, such as microorganisms.

Enantioselectivity: the production of chiral molecules with high enantiomeric excess, which is very important in the pharmaceutical industry [4].

Examples

Lipases: Used in the synthesis of chiral intermediates for pharmaceuticals.

Nitrilases: Employed for the synthesis of chiral carboxylic acids and amides.

Transaminases: Used for the synthesis of chiral amines.

Biotransformation: whole-cell catalysis

Biotransformation utilizes whole cells, such as bacteria or fungi, to perform chemical transformations. Whole cells offer the advantage of containing multiple enzymes and cofactors, enabling complex multi-step reactions [5].

Advantages of biotransformation

Complex multi-step reactions: Whole cells can perform multiple enzymatic reactions in a single step, simplifying complex syntheses.

Cofactor regeneration: Whole cells can regenerate essential cofactors, reducing the need for external addition [6].

Cost-effectiveness: Whole-cell systems can be more cost-effective than isolated enzymes, especially for complex reactions.

Tolerance to substrates: Whole cells can sometimes tolerate higher substrate concentrations than isolated enzymes [7].

Examples

Microbial fermentation: Used for the production of antibiotics and other pharmaceuticals.

Steroid modifications: Microbial biotransformations are used to modify steroid structures.

Aromatic hydroxylation: Used to introduce hydroxyl groups into aromatic compounds.

Green chemistry principles in biocatalysis and

***Corresponding author:** David Schneid, Department of Biochemistry, University of Oxford, UK, E-mail: dschneider2083@gmail.com

Received: 05-Mar-2025, Manuscript No: bcp-25-164024, **Editor assigned:** 07-Mar-2025, Pre QC No: bcp-25-164024 (PQ), **Reviewed:** 21-Mar-2025, QC No: bcp-25-164024, **Revised:** 24-Mar-2025, Manuscript No: bcp-25-164024 (R), **Published:** 31-Mar-2025, DOI: 10.4172/2168-9652.1000514

Citation: David S (2025) Biocatalysis and Biotransformation: Green Chemistry Approaches in Drug Synthesis. Biochem Physiol 14: 514.

Copyright: © 2025 David S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

biotransformation

Biocatalysis and biotransformation align with several key principles of green chemistry:

Prevention: Minimizing waste generation through high selectivity.

Atom economy: Maximizing the incorporation of starting materials into the final product.

Less hazardous chemical syntheses: Utilizing enzymes and whole cells instead of toxic reagents.

Designing safer chemicals: Producing pharmaceuticals with reduced toxicity.

Safer solvents and auxiliaries: Using water or other environmentally benign solvents.

Use of renewable feedstocks: Utilizing biomass as a source of enzymes and whole cells.

Catalysis: Utilizing enzymes as highly efficient catalysts.

Reduce derivatives: Reducing the need for derivatization and deprotection steps.

Real-time analysis for pollution prevention: Monitoring reactions to minimize waste.

Inherently safer chemistry for accident prevention: Operating under mild reaction conditions.

Challenges and Future Directions

Despite the significant advantages, biocatalysis and biotransformation face challenges:

Enzyme stability and activity: Enzymes can be sensitive to environmental conditions and may require optimization for industrial applications.

Substrate scope: Some enzymes have limited substrate scope, requiring the development of new enzymes or engineered variants.

Scale-up: Scaling up biocatalytic processes from laboratory to industrial scale can be challenging.

Cost of enzymes: The cost of enzymes can be a significant factor in industrial applications.

Genetic engineering: The advancement of genetic engineering allows for the creation of enzymes with improved characteristics [8].

Metabolic engineering: Metabolic engineering can be used to optimize whole-cell biocatalytic processes.

Computational methods: Computational methods can aid in enzyme design and reaction optimization [9].

Immobilization: Immobilization of enzymes on solid supports can enhance stability and reusability [10].

Conclusion

Biocatalysis and biotransformation represent powerful and sustainable approaches to drug synthesis, aligning with the principles of green chemistry. Their high selectivity, mild reaction conditions, and potential for utilizing renewable resources offer significant advantages over traditional synthetic methods. As the pharmaceutical industry continues to prioritize environmental sustainability, biocatalytic and biotransformation processes will play an increasingly vital role. Ongoing research focused on enzyme engineering, metabolic engineering, and process optimization will further enhance the applicability of these technologies. By embracing these greener approaches, the pharmaceutical industry can minimize its environmental footprint while continuing to develop life-saving medications. The transition to biocatalytic and biotransformation methods is not just an environmental imperative but also a strategic advantage, fostering innovation and sustainability in drug synthesis.

Acknowledgement

None

Conflict of Interest

None

References

1. Nakanishi T, Nishikawa J, Hiromori Y, Yokoyama H, Koyanagi M, et al.(2005) Trialkyltin compounds bind retinoid X receptor to alter human placental endocrine functions. *Mol Endocrinol* 19: 2502–2516.
2. leMaire A, Grimaldi M, Roecklin D, Dagnino S, Vivat-Hannah V, et al. (2009) Activation of RXR-PPAR heterodimers by organotin environmental endocrine disruptors. *EMBO Rep* 10: 367–373.
3. Toporova L, Macejova D, Brtko J (2016) Radioligand binding assay for accurate determination of nuclear retinoid X receptors: A case of triorganotin endocrine disrupting ligands. *Toxicol Lett* 254: 32–36.
4. Nakanishi T (2008) Endocrine disruption induced by organotin compounds: Organotins function as a powerful agonist for nuclear receptors rather than aromatase inhibitor. *J Toxicol Sci* 33: 269–276.
5. Brtko J, Dvorak Z (2015) Triorganotin compounds—Ligands for “rexinoid” inducible transcription factors: Biological effects. *Toxicol Lett* 234: 50–58.
6. Novotny L, Sharaf L, Abdel-Hamid ME, Brtko J (2018) Stability studies of endocrine disrupting tributyltin and triphenyltin compounds in an artificial sea water model. *Gen Physiol Biophys* 37: 93–99.
7. Bodo J, Hunakova L, Kvasnicka P, Jakubikova J, Duraj J, et al. (2006) Sensitization for cisplatin-induced apoptosis by isothiocyanate E-41B leads to signaling pathways alterations. *Br J Cancer* 95: 1348–1353.
8. Bohacova V, Seres M, Pavlikova L, Kontar S, Cagala M, et al. (2018) Triorganotin derivatives induce cell death effects on L1210 leukemia cells at submicromolar concentrations independently of P-glycoprotein expression. *Molecules* 23: 10–53.
9. Unger FT, Klasen HA, Tchatchian G, Wilde RL, Witte I, et al. (2009) DNA damage induced by cis- and carboplatin as indicator for in vitro sensitivity of ovarian carcinoma cells. *BMC Cancer* 9: 359.
10. You MK, Kim HJ, Kook JH, Kim HAS (2018) John's wort regulates proliferation and apoptosis in MCF 7 human breast cancer cells by inhibiting AMPK/mTOR and activating the mitochondrial pathway. *Int J Mol Sci* 19: 966.